Top

Published in:

Open Access 01-12-2016 | Research article

Osteopontin is elevated in patients with mitral annulus calcification independent from classic cardiovascular risk factors

Authors: Michael Sponder, Christian Reuter, Monika Fritzer-Szekeres, Brigitte Litschauer, Thomas Binder, Jeanette Strametz-Juranek

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Abstract

Background

Osteopontin (OPN) regulates the Ca⁺⁺-deposition in bone and coronary arteries. Elevated OPN were also associated with (aortic) valve calcification in healthy individuals. This study aimed to investigate the association between OPN levels and mitral annulus calcification (MAC) in patients with coronary artery disease (CAD).

Methods

In this cross-sectional study OPN-levels were measured in 223 non-or ex-smoking patients (160 male, mean age: 61,09 ± 11,02 years; 63 female: mean age: 67,49 ± 7,87 years) with CAD. Plasma OPN levels were measured by ELISA and MAC was evaluated by echocardiography.

Results

Forward stepwise logistic regression analysis (likelihood quotient) showed significantly higher OPN-levels in patients with MAC compared to patient without calcified mitral annulus independent from the classic risk factors age and severity of coronary artery disease (CAD). In addition to age and the severity of CAD, the circulating OPN amount was a significant predictor for MAC.

Conclusions

This is the first clinical trial which observed increased circulating OPN levels in MAC, suggesting a distinct role of OPN in the process of MAC. Considering the current knowledge about OPN it is more likely that OPN does not promote but counteracts valve calcification and therefore is elevated in course of a calcification processes.

Fox CS, Parise H, Vasan RS, Levy D, O’Donnell CJ, D’Agostino RB, Plehn JF, Benjamin EJ. Mitral annular calcification is a predictor for incident atrial fibrillation. Atherosclerosis. 2004;173(2):291–4.CrossRefPubMed

Atar S, Jeon DS, Luo H, Siegel RJ. Mitral annular calcification: a marker of severe coronary artery disease in patients under 65 years old. Heart. 2003;89(2):161–4.CrossRefPubMedPubMedCentral

Fox CS, Vasan RS, Parise H, Levy D, O’Donnell CJ, D’Agostino RB, Benjamin EJ. Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation. 2003;107(11):1492–6.CrossRefPubMed

Price J, Glineur D, De Kerchove L, El Khoury G:. Mitral Valve Repair is Feasible Following Extensive Decalcification and Reconstruction of the Atrioventricular Groove. J Heart Valve Dis. 2015;24(1):46–52.

Zohar R, Sodek J, McCulloch CA. Characterization of stromal progenitor cells enriched by flow cytometry. Blood. 1997;90(9):3471–81.PubMed

Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 2009;28(38):3412–22.CrossRefPubMed

Giachelli CM, Schwartz SM, Liaw L. Molecular and cellular biology of osteopontin Potential role in cardiovascular disease. Trends Cardiovasc Med. 1995;5(3):88–95.CrossRefPubMed

Mohler 3rd ER, Adam LP, McClelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol. 1997;17(3):547–52.CrossRefPubMed

Canver CC, Gregory RD, Cooler SD, Voytovich MC. Association of osteopontin with calcification in human mitral valves. J Cardiovasc Surg (Torino). 2000;41(2):171–4.

10.

Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, Sebo TJ, Rosengart TK, Edwards WD, McCarthy PM, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005;111(24):3296–301.CrossRefPubMedPubMedCentral

11.

Yu PJ, Skolnick A, Ferrari G, Heretis K, Mignatti P, Pintucci G, Rosenzweig B, Diaz-Cartelle J, Kronzon I, Perk G, et al. Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis. J Thorac Cardiovasc Surg. 2009;138(1):196–9.CrossRefPubMed

12.

Sponder M, Fritzer-Szekeres M, Litschauer B, Binder T, Strametz-Juranek J. Endostatin and osteopontin are elevated in patients with both coronary artery disease and aortic valve calcification. IJC Metabolic & Endocrine. 2015;9:5–9.CrossRef

13.

Neame PJ, Butler WT. Posttranslational modification in rat bone osteopontin. Connect Tissue Res. 1996;35(1–4):145–50.CrossRefPubMed

14.

Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, Cheresh DA. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993;268(13):9901–7.PubMed

15.

Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res. 1999;84(2):166–78.CrossRefPubMed

16.

Sponder M, Fritzer-Szekeres M, Marculescu R, Litschauer B, Strametz-Juranek J. A new coronary artery disease grading system correlates with numerous routine parameters that were associated with atherosclerosis: a grading system for coronary artery disease severity. Vasc Health Risk Manag. 2014;10:641–647.

17.

Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343(9):611–7.CrossRefPubMed

18.

Kohsaka S, Jin Z, Rundek T, Boden-Albala B, Homma S, Sacco RL, Di Tullio MR. Impact of mitral annular calcification on cardiovascular events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc Imaging. 2008;1(5):617–23.CrossRefPubMedPubMedCentral

19.

Elmariah S, Budoff MJ, Delaney JA, Hamirani Y, Eng J, Fuster V, Kronmal RA, Halperin JL, O’Brien KD. Risk factors associated with the incidence and progression of mitral annulus calcification: the multi-ethnic study of atherosclerosis. Am Heart J. 2013;166(5):904–912.

20.

Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118(15):e523–661.CrossRefPubMed

21.

Shen M, Marie P, Farge D, Carpentier S, De Pollak C, Hott M, Chen L, Martinet B, Carpentier A. Osteopontin is associated with bioprosthetic heart valve calcification in humans. C R Acad Sci III. 1997;320(1):49–57.CrossRefPubMed

22.

Abdel-Azeez HA, Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal. 2010;24(3):201–206.

23.

Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161(6):2035–46.CrossRefPubMedPubMedCentral

24.

Sainger R, Grau JB, Poggio P, Branchetti E, Bavaria JE, Gorman JH, 3rd, Gorman RC, Ferrari G. Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers. 2012;17(2):111–118.

25.

Selzer A. Changing aspects of the natural history of valvular aortic stenosis. N Engl J Med. 1987;317(2):91–8.CrossRefPubMed

26.

Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim HM, Kitamura Y, Yutani C, Nomura S. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol. 1993;143(4):1003–8.PubMedPubMedCentral

27.

Sponder M, Fritzer-Szekeres M, Marculescu R, Litschauer B, Strametz-Juranek J. Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease; 2015. Heart Vessels, Epub ahead of print.

Title: Osteopontin is elevated in patients with mitral annulus calcification independent from classic cardiovascular risk factors
Authors: Michael Sponder
Christian Reuter
Monika Fritzer-Szekeres
Brigitte Litschauer
Thomas Binder
Jeanette Strametz-Juranek
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-016-0314-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Osteopontin is elevated in patients with mitral annulus calcification independent from classic cardiovascular risk factors

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity

Short-term predictive ability of selected cardiovascular risk prediction models in a rural Bangladeshi population: a case-cohort study

Effects of a home-based activation intervention on self-management adherence and readmission in rural heart failure patients: the PATCH randomized controlled trial

Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis

The association of reduced lung function with blood pressure variability in African Americans: data from the Jackson Heart Study

Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page